NO20001648L - FremgangsmÕter og mellomprodukter for fremstilling av anti- cancerforbindelser - Google Patents

FremgangsmÕter og mellomprodukter for fremstilling av anti- cancerforbindelser

Info

Publication number: NO20001648L
Authority: NO; Norway
Prior art keywords: intermediates; preparation; methods; cancer compounds; cancer
Prior art date: 1999-03-31

Application number

NO20001648A

Other languages

English (en)

Other versions

NO321952B1 (no

NO20001648D0 (no

Inventor

Richard Shelton Lehner

Timothy Norris

Dinos Paul Santafianos

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-31

Filing date

2000-03-30

Publication date

2000-10-02

2000-03-30 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2000-03-30 Publication of NO20001648D0 publication Critical patent/NO20001648D0/no

2000-10-02 Publication of NO20001648L publication Critical patent/NO20001648L/no

2006-07-24 Publication of NO321952B1 publication Critical patent/NO321952B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
- C22B15/00—Obtaining copper
- C22B15/0002—Preliminary treatment
- C22B15/0004—Preliminary treatment without modification of the copper constituent
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
- C22B15/00—Obtaining copper
- C22B15/0063—Hydrometallurgy
- C22B15/0065—Leaching or slurrying
- C22B15/0067—Leaching or slurrying with acids or salts thereof
- C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P10/00—Technologies related to metal processing
- Y02P10/20—Recycling

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Health & Medical Sciences (AREA)
Metallurgy (AREA)
Mechanical Engineering (AREA)
Materials Engineering (AREA)
Manufacturing & Machinery (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20001648A 1999-03-31 2000-03-30 Fremgangsmater og mellomprodukter for fremstilling av anti-cancerforbindelser NO321952B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US12707299P	1999-03-31	1999-03-31

Publications (3)

Publication Number	Publication Date
NO20001648D0 NO20001648D0 (no)	2000-03-30
NO20001648L true NO20001648L (no)	2000-10-02
NO321952B1 NO321952B1 (no)	2006-07-24

Family

ID=22428179

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20001648A NO321952B1 (no)	1999-03-31	2000-03-30	Fremgangsmater og mellomprodukter for fremstilling av anti-cancerforbindelser
NO20054715A NO324745B1 (no)	1999-03-31	2005-10-13	Fremgangsmater for fremstilling av anti-cancer forbindelser

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20054715A NO324745B1 (no)	1999-03-31	2005-10-13	Fremgangsmater for fremstilling av anti-cancer forbindelser

Country Status (49)

Country	Link
US (1)	US6476040B1 (no)
EP (1)	EP1044969B1 (no)
JP (2)	JP3420549B2 (no)
KR (2)	KR100430210B1 (no)
CN (2)	CN100351242C (no)
AP (2)	AP1265A (no)
AR (1)	AR018705A1 (no)
AT (1)	ATE348098T1 (no)
AU (2)	AU781402B2 (no)
BG (1)	BG65194B1 (no)
BR (1)	BRPI0001486B8 (no)
CA (2)	CA2427221C (no)
CO (1)	CO5160273A1 (no)
CR (1)	CR6165A (no)
CZ (1)	CZ299426B6 (no)
DE (1)	DE60032275T2 (no)
DK (1)	DK1044969T3 (no)
DZ (1)	DZ3030A1 (no)
EA (3)	EA004654B1 (no)
EE (1)	EE04589B1 (no)
EG (1)	EG22506A (no)
ES (1)	ES2278578T3 (no)
GE (1)	GEP20022653B (no)
GT (1)	GT200000037A (no)
HR (1)	HRP20000182B1 (no)
HU (1)	HU227698B1 (no)
ID (1)	ID25427A (no)
IL (2)	IL168036A (no)
IS (1)	IS2468B (no)
MA (1)	MA25087A1 (no)
MY (1)	MY136270A (no)
NO (2)	NO321952B1 (no)
NZ (2)	NZ503683A (no)
OA (1)	OA11335A (no)
PA (1)	PA8491901A1 (no)
PE (1)	PE20001599A1 (no)
PL (1)	PL339330A1 (no)
PT (1)	PT1044969E (no)
RS (1)	RS49836B (no)
SG (2)	SG115536A1 (no)
SK (1)	SK287339B6 (no)
SV (1)	SV2002000047A (no)
TN (1)	TNSN00064A1 (no)
TR (1)	TR200000837A2 (no)
TW (1)	TW553939B (no)
UA (2)	UA80955C2 (no)
UY (1)	UY26086A1 (no)
YU (1)	YU13200A (no)
ZA (1)	ZA200001586B (no)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6706721B1 (en)	1998-04-29	2004-03-16	Osi Pharmaceuticals, Inc.	N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (uk) *	1999-11-11	2006-02-15	Осі Фармасьютікалз, Інк.	Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en)	1999-11-11	2006-08-08	Osi Pharmaceuticals, Inc.	Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
KR100600550B1 (ko)	2000-10-20	2006-07-13	에자이 가부시키가이샤	질소 함유 방향환 유도체
US7132427B2 (en)	2001-06-21	2006-11-07	Ariad Pharmaceuticals, Inc.	Quinazolines and uses thereof
US7078409B2 (en)	2002-03-28	2006-07-18	Beta Pharma, Inc.	Fused quinazoline derivatives useful as tyrosine kinase inhibitors
ES2400339T3 (es)	2002-07-15	2013-04-09	Symphony Evolution, Inc.	Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
US7148231B2 (en) *	2003-02-17	2006-12-12	Hoffmann-La Roche Inc.	[6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
JPWO2004080462A1 (ja)	2003-03-10	2006-06-08	エーザイ株式会社	ｃ−Ｋｉｔキナーゼ阻害剤
JP5129957B2 (ja)	2003-07-03	2013-01-30	ミリアドジェネティクス，インコーポレイテッド	カスパーゼの活性化因子およびアポトーシスの誘発因子としての４−アリールアミノ−キナゾリン
WO2006074147A2 (en)	2005-01-03	2006-07-13	Myriad Genetics, Inc.	Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) *	2003-07-03	2012-11-13	Myrexis, Inc.	Compounds and therapeutical use thereof
BRPI0414489A8 (pt)	2003-09-16	2019-01-15	Astrazeneca Ab	derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina
EP2392565B1 (en)	2003-09-26	2014-03-19	Exelixis, Inc.	c-Met modulators and methods of use
WO2005044788A1 (ja)	2003-11-11	2005-05-19	Eisai Co., Ltd.	ウレア誘導体およびその製造方法
RS52119B (sr) *	2004-05-06	2012-08-31	Warner-Lambert Company Llc	4-fenilamino-hinazolin-6-il-amidi
JP4834553B2 (ja)	2004-09-17	2011-12-14	エーザイ・アール・アンド・ディー・マネジメント株式会社	医薬組成物
US8258145B2 (en)	2005-01-03	2012-09-04	Myrexis, Inc.	Method of treating brain cancer
US7625911B2 (en) *	2005-01-12	2009-12-01	Mai De Ltd.	Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
KR20070108270A (ko)	2005-02-28	2007-11-08	에자이 알앤드디 매니지먼트 가부시키가이샤	술폰아미드 화합물의 신규 병용
US20100105031A1 (en) *	2005-08-01	2010-04-29	Esai R & D Management Co., Ltd.	Method for prediction of the efficacy of vascularization inhibitor
US9006240B2 (en)	2005-08-02	2015-04-14	Eisai R&D Management Co., Ltd.	Method for assay on the effect of vascularization inhibitor
US20090053236A1 (en) *	2005-11-07	2009-02-26	Eisai R & D Management Co., Ltd.	USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
EP1964837A4 (en) *	2005-11-22	2010-12-22	Eisai R&D Man Co Ltd	Antitumor agent against multiple myeloma
RU2448708C3 (ru) *	2006-05-18	2017-09-28	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Противоопухолевое средство против рака щитовидной железы
JPWO2008001956A1 (ja) *	2006-06-29	2009-12-03	エーザイ・アール・アンド・ディー・マネジメント株式会社	肝線維症治療剤
CN101547910A (zh)	2006-07-28	2009-09-30	合成纤维有限公司	结晶埃罗替尼
CN101511793B (zh)	2006-08-28	2011-08-03	卫材R&D管理有限公司	针对未分化型胃癌的抗肿瘤剂
US8372856B2 (en)	2006-10-27	2013-02-12	Synthon Bv	Hydrates of erlotinib hydrochloride
WO2008088088A1 (ja)	2007-01-19	2008-07-24	Eisai R & D Management Co., Ltd.	膵癌治療用組成物
EP2119707B1 (en)	2007-01-29	2015-01-14	Eisai R&D Management Co., Ltd.	Composition for treatment of undifferentiated-type of gastric cancer
ES2573931T3 (es)	2007-02-21	2016-06-13	Natco Pharma Limited	Nuevos polimorfismos de clorhidrato de erlotinib y método de preparación
NZ579997A (en)	2007-04-04	2012-08-31	Cipla Ltd	PROCESS FOR PREPARATION OF N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
US20090012295A1 (en) *	2007-06-25	2009-01-08	Ales Gavenda	Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib
US8389531B2 (en)	2007-07-11	2013-03-05	Hetero Drugs Limited	Process for erlotinib hydrochloride
US20090124642A1 (en) *	2007-08-23	2009-05-14	Augusto Canavesi	Crystalline forms of Erlotinib HCI and formulations thereof
WO2009025875A1 (en) *	2007-08-23	2009-02-26	Plus Chemicals Sa	Stable formulations of crystalline erlotinib hcl
US20090076042A1 (en) *	2007-09-15	2009-03-19	Protia, Llc	Deuterium-enriched erlotinib
WO2009060945A1 (ja)	2007-11-09	2009-05-14	Eisai R & D Management Co., Ltd.	血管新生阻害物質と抗腫瘍性白金錯体との併用
EP2248804A4 (en) *	2008-01-29	2014-09-10	Eisai R&D Man Co Ltd	COMBINED USE OF AN ANGIOGENESIS INHIBITOR AND A TAXANE
CN102083801A (zh) *	2008-03-28	2011-06-01	康瑟特制药公司	喹唑啉衍生物和治疗方法
KR20110017907A (ko) *	2008-07-07	2011-02-22	플러스 케미칼스, 에스.에이.	엘로티닙 염기 및 엘로티닙 ｈｃｌ의 결정형
KR101132937B1 (ko)	2008-10-01	2012-04-06	주식회사종근당	Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (en) *	2008-10-08	2010-04-15	Apotex Pharmachem Inc.	Processes for the preparation of erlotinib hydrochloride
PT2387563E (pt)	2009-01-16	2013-03-25	Exelixis Inc	Sal de malato de n-(4-{[6,7-bis(metiloxi)quinolin-4- il]oxi}fenil)-n¿-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, e suas formas cristalinas para o tratamento de cancro
US8440823B2 (en)	2009-03-26	2013-05-14	Ranbaxy Laboratories Limited	Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20120302749A1 (en)	2009-11-12	2012-11-29	Ranbaxy Laboratories Limited	Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en)	2009-12-02	2011-06-09	Ultimorphix Technologies B.V.	Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
AU2011270165B2 (en)	2010-06-25	2015-12-24	Eisai R&D Management Co., Ltd.	Antitumor agent using compounds having kinase inhibitory effect in combination
JP5948597B2 (ja)	2010-07-23	2016-07-06	ジェネリクス・［ユーケー］・リミテッド	純粋なエルロチニブ
IT1402029B1 (it) *	2010-10-14	2013-08-28	Italiana Sint Spa	Procedimento per la preparazione di erlotinib
JP6021805B2 (ja)	2011-04-18	2016-11-09	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍治療剤
EP3444363B1 (en)	2011-06-03	2020-11-25	Eisai R&D Management Co., Ltd.	Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102267952B (zh) *	2011-06-21	2013-12-11	天津市汉康医药生物技术有限公司	喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) *	2012-05-25	2016-08-31	浙江九洲药业股份有限公司	一种盐酸埃罗替尼晶型a的制备方法
US9593083B2 (en)	2012-09-04	2017-03-14	Shilpa Medicare Limited	Crystalline erlotinib hydrochloride process
JPWO2014098176A1 (ja)	2012-12-21	2017-01-12	エーザイ・アール・アンド・ディー・マネジメント株式会社	キノリン誘導体のアモルファス及びその製造方法
WO2014118737A1 (en)	2013-01-31	2014-08-07	Ranbaxy Laboratories Limited	Erlotinib salts
CN105264380B (zh)	2013-05-14	2017-09-05	卫材R&D管理有限公司	用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
CN103333124B (zh) *	2013-05-28	2015-03-25	埃斯特维华义制药有限公司	一种制备盐酸厄洛替尼晶型f的方法
SMT202200367T1 (it)	2014-08-28	2022-11-18	Eisai R&D Man Co Ltd	Derivato di chinolina a elevata purezza e metodo per la produzione dello stesso
CA2908441A1 (en)	2014-10-28	2016-04-28	Cerbios-Pharma Sa	Process for the preparation of erlotinib
CA2976325C (en)	2015-02-25	2023-07-04	Eisai R&D Management Co., Ltd.	Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko)	2015-03-04	2024-05-02	머크 샤프 앤드 돔 코포레이션	암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN107801379B (zh)	2015-06-16	2021-05-25	卫材R&D管理有限公司	抗癌剂
AU2016309356B2 (en)	2015-08-20	2021-06-24	Eisai R&D Management Co., Ltd.	Tumor therapeutic agent
CN105884653A (zh) *	2016-06-08	2016-08-24	浙江汇能生物股份有限公司	一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) *	2016-08-26	2017-01-04	宁波圣达精工智能科技有限公司	一种阻燃智能密集书架的制备方法
ES2971448T3 (es)	2017-02-08	2024-06-05	Eisai R&D Man Co Ltd	Composición farmacéutica para el tratamiento de tumores
CA3061888A1 (en)	2017-05-16	2018-11-22	Eisai R&D Management Co., Ltd.	Treatment of hepatocellular carcinoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4747498A (en) *	1986-06-27	1988-05-31	Sunbeam Plastics Corporation	Safety dispensing closure-container package
AU661533B2 (en) *	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
JP2657760B2 (ja) *	1992-07-15	1997-09-24	小野薬品工業株式会社	４−アミノキナゾリン誘導体およびそれを含有する医薬品
WO1996030347A1 (en) *	1995-03-30	1996-10-03	Pfizer Inc.	Quinazoline derivatives
US5747498A (en) *	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
JP4471404B2 (ja)	1996-02-13	2010-06-02	アストラゼネカユーケイリミテッド	Ｖｅｇｆインヒビターとしてのキナゾリン誘導体
KR100489174B1 (ko)	1996-03-05	2005-09-30	제네카-파마 소시에떼아노님	4-아닐리노퀴나졸린유도체
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
US6225499B1 (en)	1997-07-14	2001-05-01	Catalytica Pharmaceuticals, Inc.	Process for preparing aminoarylacetylenes
AU759691C (en)	1998-04-29	2004-04-29	Osi Pharmaceuticals, Inc.	N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4- quinazolinamine mesylate anhydrate and monohydrate

2000
- 2000-03-03 YU YU13200A patent/YU13200A/sh unknown
- 2000-03-03 RS YUP-132/00A patent/RS49836B/sr unknown
- 2000-03-10 OA OA1200000071A patent/OA11335A/en unknown
- 2000-03-14 CR CR6165A patent/CR6165A/es unknown
- 2000-03-17 PA PA20008491901A patent/PA8491901A1/es unknown
- 2000-03-20 DE DE60032275T patent/DE60032275T2/de not_active Expired - Lifetime
- 2000-03-20 PT PT00302256T patent/PT1044969E/pt unknown
- 2000-03-20 ES ES00302256T patent/ES2278578T3/es not_active Expired - Lifetime
- 2000-03-20 AT AT00302256T patent/ATE348098T1/de not_active IP Right Cessation
- 2000-03-20 EP EP00302256A patent/EP1044969B1/en not_active Expired - Lifetime
- 2000-03-20 DK DK00302256T patent/DK1044969T3/da active
- 2000-03-21 IS IS5411A patent/IS2468B/is unknown
- 2000-03-22 CO CO00020444A patent/CO5160273A1/es unknown
- 2000-03-23 IL IL168036A patent/IL168036A/en not_active IP Right Cessation
- 2000-03-23 IL IL13524500A patent/IL135245A0/xx not_active IP Right Cessation
- 2000-03-27 SG SG200302185A patent/SG115536A1/en unknown
- 2000-03-27 SK SK444-2000A patent/SK287339B6/sk not_active IP Right Cessation
- 2000-03-27 BR BRPI0001486A patent/BRPI0001486B8/pt not_active IP Right Cessation
- 2000-03-27 ID IDP20000240A patent/ID25427A/id unknown
- 2000-03-27 UA UA20040503766A patent/UA80955C2/uk unknown
- 2000-03-27 UA UA2000031727A patent/UA70928C2/uk unknown
- 2000-03-27 SG SG200001746A patent/SG121687A1/en unknown
- 2000-03-27 TW TW089105605A patent/TW553939B/zh not_active IP Right Cessation
- 2000-03-27 EG EG20000364A patent/EG22506A/xx active
- 2000-03-28 AU AU22620/00A patent/AU781402B2/en not_active Expired
- 2000-03-28 BG BG104278A patent/BG65194B1/bg unknown
- 2000-03-29 DZ DZ000059A patent/DZ3030A1/xx active
- 2000-03-29 MY MYPI20001252A patent/MY136270A/en unknown
- 2000-03-29 UY UY26086A patent/UY26086A1/es not_active Application Discontinuation
- 2000-03-29 TN TNTNSN00064A patent/TNSN00064A1/fr unknown
- 2000-03-29 JP JP2000091300A patent/JP3420549B2/ja not_active Expired - Lifetime
- 2000-03-29 AR ARP000101413A patent/AR018705A1/es active IP Right Grant
- 2000-03-29 AP APAP/P/2000/001778A patent/AP1265A/en active
- 2000-03-29 AP APAP/P/2003/002757D patent/AP1655A/en active
- 2000-03-29 CA CA002427221A patent/CA2427221C/en not_active Expired - Lifetime
- 2000-03-29 MA MA25940A patent/MA25087A1/fr unknown
- 2000-03-29 ZA ZA200001586A patent/ZA200001586B/xx unknown
- 2000-03-29 CA CA002302965A patent/CA2302965C/en not_active Expired - Lifetime
- 2000-03-30 EE EEP200000255A patent/EE04589B1/xx not_active IP Right Cessation
- 2000-03-30 NO NO20001648A patent/NO321952B1/no not_active IP Right Cessation
- 2000-03-30 PL PL00339330A patent/PL339330A1/xx not_active Application Discontinuation
- 2000-03-30 GT GT200000037A patent/GT200000037A/es unknown
- 2000-03-30 EA EA200000274A patent/EA004654B1/ru not_active IP Right Cessation
- 2000-03-30 EA EA200201244A patent/EA005561B1/ru not_active IP Right Cessation
- 2000-03-30 SV SV2000000047A patent/SV2002000047A/es not_active Application Discontinuation
- 2000-03-30 TR TR2000/00837A patent/TR200000837A2/xx unknown
- 2000-03-30 HU HU0001353A patent/HU227698B1/hu unknown
- 2000-03-30 EA EA200201245A patent/EA005892B1/ru not_active IP Right Cessation
- 2000-03-30 PE PE2000000277A patent/PE20001599A1/es not_active Application Discontinuation
- 2000-03-30 NZ NZ503683A patent/NZ503683A/en not_active IP Right Cessation
- 2000-03-30 NZ NZ512818A patent/NZ512818A/xx not_active IP Right Cessation
- 2000-03-30 KR KR1020000016386A patent/KR100430210B1/ko not_active Expired - Lifetime
- 2000-03-30 US US09/538,635 patent/US6476040B1/en not_active Expired - Lifetime
- 2000-03-30 CZ CZ20001155A patent/CZ299426B6/cs not_active IP Right Cessation
- 2000-03-31 CN CNB2005100763600A patent/CN100351242C/zh not_active Expired - Lifetime
- 2000-03-31 CN CNB001045954A patent/CN1215061C/zh not_active Expired - Lifetime
- 2000-03-31 GE GEAP20005284A patent/GEP20022653B/en unknown
- 2000-03-31 HR HR20000182A patent/HRP20000182B1/xx not_active IP Right Cessation
2002
- 2002-07-29 KR KR10-2002-0044610A patent/KR100430209B1/ko not_active Expired - Lifetime
- 2002-12-12 JP JP2002360742A patent/JP4074509B2/ja not_active Expired - Lifetime
2005
- 2005-04-08 AU AU2005201494A patent/AU2005201494B2/en not_active Expired
- 2005-10-13 NO NO20054715A patent/NO324745B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CO5160273A1 (es)	2002-05-30
TW553939B (en)	2003-09-21
AU2005201494A1 (en)	2005-05-05
EA005892B1 (ru)	2005-06-30
ZA200001586B (en)	2001-10-01
MY136270A (en)	2008-09-30
IL135245A0 (en)	2001-05-20
IS2468B (is)	2008-12-15
EP1044969B1 (en)	2006-12-13
NO321952B1 (no)	2006-07-24
PA8491901A1 (es)	2001-12-14
SG115536A1 (en)	2005-10-28
EA200201245A1 (ru)	2003-04-24
CN1276370A (zh)	2000-12-13
AP1265A (en)	2004-03-26
CN1699350A (zh)	2005-11-23
CA2427221A1 (en)	2000-09-30
NO20054715L (no)	2000-10-02
DZ3030A1 (fr)	2004-03-27
BG65194B1 (bg)	2007-06-29
NO324745B1 (no)	2007-12-03
TNSN00064A1 (fr)	2005-11-10
US6476040B1 (en)	2002-11-05
KR100430210B1 (ko)	2004-05-03
HK1029790A1 (en)	2001-04-12
IS5411A (is)	2000-10-02
NZ503683A (en)	2001-09-28
NO20001648D0 (no)	2000-03-30
JP2000290262A (ja)	2000-10-17
GT200000037A (es)	2001-09-21
ATE348098T1 (de)	2007-01-15
KR100430209B1 (ko)	2004-05-03
HU227698B1 (en)	2011-12-28
CR6165A (es)	2008-10-10
AU2005201494B2 (en)	2008-02-07
OA11335A (en)	2003-12-10
HU0001353D0 (en)	2000-06-28
GEP20022653B (en)	2002-03-25
UA70928C2 (uk)	2004-11-15
RS49836B (sr)	2008-08-07
EA004654B1 (ru)	2004-06-24
BRPI0001486B8 (pt)	2021-05-25
HUP0001353A3 (en)	2002-01-28
UY26086A1 (es)	2000-10-31
HRP20000182B1 (en)	2007-10-31
IL168036A (en)	2006-12-10
CA2302965A1 (en)	2000-09-30
JP4074509B2 (ja)	2008-04-09
EA200000274A3 (ru)	2003-02-27
CA2427221C (en)	2008-09-16
CN1215061C (zh)	2005-08-17
SK287339B6 (sk)	2010-07-07
AP2000001778A0 (en)	2000-03-31
AU2262000A (en)	2000-10-05
PL339330A1 (en)	2000-10-09
AP1655A (en)	2006-09-01
EP1044969A3 (en)	2000-11-29
HRP20000182A2 (en)	2001-04-30
TR200000837A2 (tr)	2000-11-21
DK1044969T3 (da)	2007-04-23
SK4442000A3 (en)	2000-10-09
BRPI0001486B1 (pt)	2019-01-29
KR20020084903A (ko)	2002-11-13
PE20001599A1 (es)	2001-01-18
DE60032275D1 (de)	2007-01-25
CZ20001155A3 (cs)	2001-03-14
AU781402B2 (en)	2005-05-19
EE200000255A (et)	2000-12-15
NZ512818A (en)	2003-01-31
JP2003176274A (ja)	2003-06-24
CZ299426B6 (cs)	2008-07-23
KR20010014658A (ko)	2001-02-26
BR0001486A (pt)	2001-05-02
UA80955C2 (en)	2007-11-26
CN100351242C (zh)	2007-11-28
MA25087A1 (fr)	2000-10-01
AR018705A1 (es)	2001-11-28
SV2002000047A (es)	2002-01-23
JP3420549B2 (ja)	2003-06-23
YU13200A (sh)	2002-10-18
BG104278A (en)	2001-08-31
CA2302965C (en)	2004-02-17
ES2278578T3 (es)	2007-08-16
EA200201244A1 (ru)	2003-04-24
HUP0001353A2 (hu)	2001-05-28
EA005561B1 (ru)	2005-04-28
EA200000274A2 (ru)	2000-10-30
SG121687A1 (en)	2006-05-26
EG22506A (en)	2003-03-31
EP1044969A2 (en)	2000-10-18
DE60032275T2 (de)	2007-07-12
EE04589B1 (et)	2006-02-15
ID25427A (id)	2000-10-05
PT1044969E (pt)	2007-05-31

Publication	Publication Date	Title
NO20001648L (no)	2000-10-02	FremgangsmÕter og mellomprodukter for fremstilling av anti- cancerforbindelser
CY2007029I1 (el)	2009-11-04	Μεθοδος για την παρασκευη υποκατεστημενων οκτανοϋλ-αμιδιων
NO20021382L (no)	2002-05-16	Fremgangsmåter og mikroorganismer for fremstilling av panto- forbindelser
NO20022895L (no)	2002-06-20	Fremgangsmåter for fremstilling av karotenoider og for fremstilling av fôrmaterialer
EE200100259A (et)	2002-12-16	Moksifloksatsiini farmatseutiline preparaat
PT1150966E (pt)	2003-01-31	Metodo de preparacao de 5-cianoftalido
CY2009001I1 (el)	2009-11-04	Νεα μορφη κρυσταλλου του παραγωγου πυρρολιδυλοθειοκαρβαπενεμης
NO20015542L (no)	2002-01-14	Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
EE04234B1 (et)	2004-02-16	L-fenüülefriinvesinikkloriidi valmistamise meetod
NO20020622D0 (no)	2002-02-08	Polymorfer av torsemid
NO20021124L (no)	2002-05-08	Fremgangsmåte for fremstilling av benzoksazinderivater og mellomprodukter derfor
NO20016151D0 (no)	2001-12-17	Fremstilling av substituerte piperidin-4-oner
NO20030515D0 (no)	2003-02-03	Fremgangsmåte for fremstilling av dinapsolin
DK1339723T3 (da)	2006-06-12	Fremgangsmåde og ester derivater anvendelige til fremstilling af cefalosporiner
PT1178984E (pt)	2003-06-30	Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano
ID30381A (id)	2001-11-29	Penggunaan arilalkanoilpiridazina
NO20032297L (no)	2003-05-21	Fremgangsmåte for fremstilling av distamycinderivater
NO20023702D0 (no)	2002-08-06	Fremgangsmåte for fremstilling av 5-arylnikotinaldehyder
NO20020328D0 (no)	2002-01-22	Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
NO990185L (no)	1999-07-19	FremgangsmÕte for fremstilling av naftypyridoner og mellomprodukter
NO20020327D0 (no)	2002-01-22	Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol
IS5212A (is)	2001-02-17	Bætt aðferð til framleiðslu á pýrazólópýrimidínónafleiðu
NO20002558D0 (no)	2000-05-18	FremgangsmÕte for fremstilling av findisperse eksplosivstoffer
EE200200053A (et)	2003-04-15	Isoretinoiini valmistamise protsess
ITMI991329A0 (it)	1999-06-15	Procedimento per la preparazione di tetrafluoroalogenobenzeni

Legal Events

Date	Code	Title	Description
2011-10-24	MM1K	Lapsed by not paying the annual fees